ArticleThe Journal of infectious diseases2022
Plasma SARS-CoV-2 RNA Levels as a Biomarker of Lower Respiratory Tract SARS-CoV-2 Infection in Critically Ill Patients With COVID-19.
Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.The Journal of infectious diseases · 2024Trial
- Oral and gut microbiota relate to symptom subphenotypes in long COVID, independent of viral persistence.iScience · 2025Article
- Acute SARS-CoV-2 infection.Nature reviews. Disease primers · 2025Review
- Droplet Digital PCR or Real-Time PCR as a Method for Quantifying SARS-CoV-2 RNA in Plasma-Is There a Difference?Viruses · 2025Article
- Age dependent susceptibility and immune responses to La Crosse virus infection in non-human primates.Scientific reports · 2025Article
- SARS-CoV-2 viremia but not respiratory viral load is associated with respiratory complications in patients with severe COVID-19.BMC pulmonary medicine · 2024Article
- Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis.BMJ open · 2024Observational
- The Role of Extracellular Vesicles in SARS-CoV-2-Induced Acute Kidney Injury: An Overview.Life (Basel, Switzerland) · 2024Review
- Trajectories of Host-Response Subphenotypes in Patients With COVID-19 Across the Spectrum of Respiratory Support.CHEST critical care · 2023Article
- Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA.iScience · 2023Article
- Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19.The Journal of antimicrobial chemotherapy · 2023Article
- Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study.The Lancet. Microbe · 2023Article
- Observational
- Plasma SARS-CoV-2 RNA elimination and RAGE kinetics distinguish COVID-19 severity.Clinical & translational immunology · 2023Article
- Ultrarapid and ultrasensitive detection of SARS-CoV-2 antibodies in COVID-19 patients via a 3D-printed nanomaterial-based biosensing platform.Journal of medical virology · 2022Article
- Correlation of SARS-CoV-2 Nasopharyngeal CT Values With Viremia and Mortality in Adults Hospitalized With COVID-19.Open forum infectious diseases · 2022Article
- Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".Current transplantation reports · 2022Review
Corrections and comments
- Update of
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Plasma SARS-CoV-2 viral RNA (vRNA) levels are predictive of COVID-19 outcomes in hospitalized patients, but whether plasma vRNA reflects lower respiratory tract (LRT) vRNA levels is unclear. We compared plasma and LRT vRNA levels in serially collected samples from mechanically ventilated patients with COVID-19. LRT and plasma vRNA levels were strongly correlated at first sampling (n = 33, r = 0.83, P < 10-9) and then declined in parallel in available serial samples except in nonsurvivors who exhibited delayed vRNA clearance in LRT samples. Plasma vRNA measurement may offer a practical surrogate of LRT vRNA burden in critically ill patients, especially early after ICU admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.